DSIP Reference

Educational, not medical advice reference for DSIP: Sleep; regulatory status, evidence posture, source review, and schedule notes. Also known as…

Plain English

What it is
DSIP is short for delta sleep-inducing peptide. It is a small, lab-made piece of protein that researchers first found decades ago in animal sleep studies. It is a research peptide, not an approved medicine.
What people use it for
People in the sleep community try it hoping for deeper, more restful sleep. Reports are mixed. Some say they sleep more deeply, and others notice nothing at all.
What the science shows
The human studies are old and small, and in them the peptide was put straight into a vein, not the way people use it on their own. That early work noted some sleep effects, but it is far from enough to prove it works as a real sleep treatment today.
The catch
DSIP is not FDA-approved, and it is not a treatment for insomnia or any sleep disorder. Because the published human evidence is dated, small, and mostly from injections into a vein, everyday community use reaches well beyond what the research actually tested.

Reference summary

Older human experiments reported sleep-related effects after intravenous dosing, but the literature is small, dated, and not enough to establish a modern clinical role.

Regulatory and posture

Categories
Sleep
Aliases
Delta sleep-inducing peptide, Emideltide
Evidence posture
human - Older small human sleep studies only.
Regulatory status
No FDA-approved DSIP/emideltide drug label. Emideltide (DSIP) was considered by FDA for inclusion on the section 503A bulk drug substances compounding list at the Pharmacy Compounding Advisory Committee meeting of July 24, 2026, where the committee narrowly recommended against inclusion; it remains not FDA-approved and is not cleared for compounding.
Content review status
research reference

Selected public sources

Related tools

For research and educational purposes only. Not medical advice.